

Production of polyclonal and monoclonal antibodies

Monoclonal Antibodies

Article types

Clinical Trial
Review
Customize ...

Text availability

Abstract
Free full text
Full text

Publication dates

Years
10 years
Custom range...

Species

Humans
Other Animals

Learn all

How additional filters

Format: Summary Sort by: Most Recent Per page: 20

Send to

Filter your results:

All (1314002)

Scientific Library - CRO Aviano
(700683)

English (1165238)

Free Full Text (375367)

Review (114476)

Manage Filter

Sort by:

Best match

Most recent

Results by year

Download CS

Related searches

monoclonal antibody

bispecific antibody

antibody drug conjugate

antibody mediated rejection

antibody production

Search results

Items: 1 to 20 of 1314002

<< First < Prev Page 1 of 65701 Next > Last >>

- [Assessment of the higher order structure of Humira®, Remicade®, Avastin®, Rituxan®, Herceptin®, and Enbrel® by 2D-NMR fingerprinting.](#)
Hodgson DJ, Ghasriani H, Aubin Y.
J Pharm Biomed Anal. 2018 Oct 1;163:144-152. doi: 10.1016/j.jpba.2018.09.056. [Epub ahead of print]
PMID: 30296716
[Similar articles](#)
- [Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET.](#)
Kwon YD, Kang S, Park H, Cheong IK, Chang KA, Lee SY, Jung JH, Lee BC, Lim ST, Kim HK.
Eur J Med Chem. 2018 Sep 29;159:292-306. doi: 10.1016/j.ejmech.2018.09.069. [Epub ahead of print]
PMID: 30296688
[Similar articles](#)
- [A comparison among \$\beta\$ -caseins purified from milk of different species: Self-assembling behaviour and immunogenicity potential.](#)
Perinelli DR, Bonacucina G, Cespi M, Bonazza F, Palmieri GF, Pucciarelli S, Polzonetti V, Attarian L, Polidori P, Vincenzetti S.
Colloids Surf B Biointerfaces. 2018 Oct 1;173:210-216. doi: 10.1016/j.colsurfb.2018.09.079. [Epub ahead of print]
PMID: 30296645
[Similar articles](#)
- [Diagnosis of T-cell mediated kidney rejection in formalin fixed paraffin embedded tissues using RNA-Seq based machine learning algorithms.](#)
Liu P, Tseng G, Wang Z, Yuchen Huang BS, Randhawa P.
Hum Pathol. 2018 Oct 5. pii: S0046-8177(18)30377-0. doi: 10.1016/j.humpath.2018.09.013. [Epub ahead of print]
PMID: 30296518
[Similar articles](#)

Pubmed
Oct 2018

Monoclonal Antibodies

Article types
Clinical Trial
Review
Customize ...

Text availability
Abstract
Free full text
Full text

Publication dates
5 years
10 years
Custom range...

Species
Humans
Other Animals

[Clear all](#)

[Show additional filters](#)

Format: Summary Sort by: Most Recent Per page: 20

Send to Filters: [Manage Filters](#)

Best matches for antibody:

[Engineering antibody therapeutics.](#)

Chiu ML et al. *Curr Opin Struct Biol.* (2016)

[Less is More: A Comparison of Antibody-Gold Nanoparticle Conjugates of Different Ratios.](#)

Byzova NA et al. *Bioconjug Chem.* (2017)

[Polyclonal and monoclonal antibodies in clinic.](#)

Wootla B et al. *Methods Mol Biol.* (2014)


[Switch to our new best match sort order](#)

Sort by:

[Best match](#)

[Most recent](#)

Results by year



[Download CSV](#)

Search results

Items: 1 to 20 of 1355548

<< First < Prev Page 1 of 67778 Next > Last >>

[Interest of Locally Weighted Regression to overcome non-linear effects during in situ NIR monitoring of CHO cell culture parameters and antibody glycosylation.](#)

1. Zavala-Ortiz DA, Ebel B, Li MY, Barradas-Dermitt DM, Hayward-Jones PM, Aguilar-Uscanga MG, Marc A, Guedon E.

Biotechnol Prog. 2019 Oct 6:e2924. doi: 10.1002/btpr.2924. [Epub ahead of print]

PMID: 31587521

[Similar articles](#)

[Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production.](#)

2. Coronel J, Heinrich C, Klausning S, Noll T, Figueredo-Cardero A, Castilho LR.

Biotechnol Prog. 2019 Oct 6:e2915. doi: 10.1002/btpr.2915. [Epub ahead of print]

PMID: 31587517

[Similar articles](#)

[Clearance of Solvents and Small Molecule Impurities in Antibody Drug Conjugates via Ultrafiltration and Diafiltration Operation.](#)

3. Gates J, Liu YF, Fang X, Liu X

Related searches

monoclonal antibody

bispecific antibody

antibody drug conjugate

neutralizing antibody

antiphospholipid antibody

Titles with your search terms

Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug α [Eur J Cancer. 2019]

Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 F [Immunity. 2019]

NUP62: the target of an anti-sperm auto-monoclonal antibody during [Reproduction. 2019]

[See more...](#)

Monoclonal Antibodies



antibody



Search

[Advanced](#) [Create alert](#) [Create RSS](#)

[User Guide](#)

Save

Email

Send to

Sorted by: Most recent


Display options

MY NCBI FILTERS

1,503,467 results

Page 1 of 15,035

RESULTS BY YEAR



TEXT AVAILABILITY

- Abstract
- Free full text
- Full text

ARTICLE ATTRIBUTE

- Associated data

ARTICLE TYPE

- Books and Documents
- Clinical Trial
- Meta-Analysis

Showing results for *antibody*

Search for *antibody* instead (1 results)

[Neuromuscular organization and haptoral armament of *Polyclithrum ponticum* \(Monogenea: Gyrodactylidae\).](#)

1
Cite Petrov AA, Dmitrieva EV, Plaksina MP.

J Helminthol. 2022 Oct 13;96:e74. doi: 10.1017/S0022149X22000608.

Share
PMID: 36226664

Musculature was stained by phalloidin, the nervous system by anti-serotonin and anti-FMRamide **antibodies**, and haptoral sclerites were visualized in reflected light. ...The arrangement of sclerites and muscles suggests that *Polyclithrum* initiates the attachment by clamping ...

[Clinical impact of antineutrophil cytoplasmic **antibody** positivity on the occurrence of interstitial lung disease in patients with polymyositis/dermatomyositis.](#)


2
Cite Ha JW, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW.

Share
Ann Palliat Med. 2022 Sep 30;apm-22-604. doi: 10.21037/apm-22-604. Online ahead of print.


PMID: 36226644

BACKGROUND: This study investigated the clinical impact of antineutrophil cytoplasmic **antibody** (ANCA) positivity on the occurrence of interstitial lung disease (ILD) in patients with probable and definite polymyositis (PM)/dermatomyositis (DM) who met both the Bohan and Pe ...


Use of monoclonal antibodies




ELISA



Immuno-histochemistry




Purification




Immuno-precipitation


Use of monoclonal antibodies



Immuno-
fluorescence



Flow cytometry



Immunoblotting

Antibody Production

Polyclonal:


Antibodies are collected from sera of exposed animal,

- or -


a combination of monoclonal colonies is combined.

Can be any animal: **Rabbit**, **Goat**, Horse, Rat, Sheep, etc...

Suite of antibodies recognizing multiple antigenic sites of injected biochemical.



Timing for Ab production



Disadvantages of Polyclonal Antisera

- Antiserum is composed of a mixture of **high** and **low** affinity antibody populations
- Antiserum is composed of a **mixture of antibodies** with different specificities - not all recognize the target of interest
- If the animal has had an infection, antibodies against the infecting organism will be present - can lead to “**non-specific**” **binding**
- **Quantity** of antiserum is **limited** by amount of serum and **life of immunized animal**.
- **Antigen must be pure.**

Advantages of Polyclonal Antisera

- Antiserum recognizes many different epitopes on the target
- Can usually be used for many different research procedures
(Immunohistochemistry, immunofluorescence, immunoprecipitation, ELISA, precipitation assays, functional assay)
- Can be affinity purified to eliminate the non-specific binding antibodies

Production of monoclonal antibodies

One of the most important example of induction and selection of stable cell mutant and cell fusion is the production of **hybridoma**

Hybridomas are hybrid of cells obtained fusing lymphocytes and a tumor cell line obtained from multiple myeloma.

The aim is to obtain a stable clone of lymphocytes in order to obtain in vitro, for long time and in high amount, monoclonal antibodies that usually lymphocytes produce after their differentiation to plasma cells.



Georges Köhler
(1946-1995)

&



Cesar Milstein
(1927-2002)

Nature Vol. 256 August 7 1975

**Continuous cultures of fused cells
secreting antibody of predefined specificity**

Method to produce monoclonal antibodies -1975


Nobel Prize - 1984

The ultimate guide to antibody production

Hybridoma technology

Monoclonal production

Individual hybridoma cells have the **ability to reproduce** and secrete the antibody of interest while continuing to proliferate indefinitely



Timelines

The generation of hybridomas and production of mAbs can take several months depending on the immunogenicity of the antigen. Once the hybridoma is stabilized, **unlimited amounts** of antibody can be produced in a relatively short time

Advantages

The principal advantages of mAbs over pAbs are **homogeneity and consistency**



Cost-effective

Following isolation of a single hybridoma, these cells can serve as a **quick, constant, cost-effective and renewable** source of a specific mAb. Cell lines can be retained for decades to produce an endless supply of mAb

Applicability

For antibodies that perform well in downstream applications, these clones are an **invaluable resource** for the research, diagnostic and therapeutic communities




How to make a monoclonal antibody

1. Immunize mice
2. Test the serum
3. Purify lymphocytes from the spleen
4. Perform a fusion
5. Screen the fusion for the right cells
6. Grow the hybridomas
7. Harvest the antibody
8. Concentrate and purify the product

Production of Monoclonal Antibodies

Immunisation with
antigen




Ab titre from serum

Ab_1 Ab_2 ... Ab_n

Immunize the mice - Inoculation

- The mice are aseptically inoculated with the antigen combined with an adjuvant.
- Inoculations are done either **sub-cutaneously** or **intra-peritoneally**.
- Normal dose per mouse is between **20 and 100 micrograms** of protein.
- Inoculations are performed every 14 to 21 days.


Timing for Ab production




Test the serum - Decision time

- When the serum titer of the mice has reached a plateau, an additional ELISA test is performed to determine the predominant *isotype* present. The two *isotypes* that are most common in mouse serum are IgG and IgM.
 - A *fusion* is done when the IgG level is high and the IgM level is low.
- Sometimes additional testing is done (Western blots, immunofluorescence) to determine whether the serum response is specific for the selected antigen.
 - The mouse with the strongest, most specific response is chosen for the fusion.


Production of Monoclonal Antibodies




Production of Monoclonal Antibodies




Production of Monoclonal Antibodies






Cell types present after fusion




What does HAT do?

- Myeloma cell fusion partners were selected for **the loss of the ability to synthesize hypoxanthine-guanine phosphoribosyl transferase (HGPRT)**
- HGPRT enables cells to synthesize purines using an extracellular source of hypoxanthine as a precursor.
- Normally, the absence of HGPRT is not a problem because cells have an alternate biochemical pathway (termed the rescue pathway) they use to synthesize purines. The rescue pathway allows myeloma cells to divide normally.
- **The rescue pathway is inhibited by aminopterin.** In the presence of aminopterin, HGPRT is essential for survival.
- HAT contains:
 - Hypoxanthine
 - Aminopterin
 - Thymidine
- HAT is selective for fused, (hybridoma) cells because:
 - Unfused myeloma cells cannot grow because they lack HGPRT
 - Unfused normal spleen cells cannot grow indefinitely because of their limited life span.
- In hybridomas the spleen cell partner supplies HGPRT and the myeloma partner is immortal because it is a cancer cell, overcoming the growth block of spleen cells.

Production of Monoclonal Antibodies



Cell types present after fusion




Hybrids of myelomas and plasma cell

Survive


Perform a fusion - Growing the cells (hybridomas)

- Cells are grown in a 37° C incubator.
- Cells are kept in an atmosphere of about 5% CO₂.
- The cells are fed after 7 days of incubation.
- The cells are checked for growth after 10 days of incubation.







Production of Monoclonal Antibodies



Production of Monoclonal Antibodies



Production of Monoclonal Antibodies





Advantages

1. Possible to select mAbs with the **required specificity**.
2. **Large quantities** of antibodies can be obtained easily.
3. **Pure antibodies** can be obtained more easily.
4. **Indefinite supply**.

Disadvantages of Monoclonal Antibodies

1. Labour intensive.
2. Costly.
3. Longer time span.

Roller bottles


- Old technology, principally for attached cell culture
- Bottle rotates at 1-3 rpm
- Effective OTR related to rotation speed and operating volume
- Scalable by replication



Bioreactors for Suspension Systems (examples)



Disposable systems





1-25 L



10-100 L

<http://www.wavebiotech.com/>





20,000 liter mammalian cell fermentor - Lonza Biologics - Portsmouth, NH

Cost (in 2015)

- Facilities cost \$20-50 million to build
- Antibodies cost \$500-1,000/gram

- High costs present challenges for reimbursement in chronic diseases

High level production in mammalian cells: the math

Lonza (contract manufacturer) claims = **5.5 g/L yield in 24 days**

30,000 L reactor:

30,000 L. X 5.5 g/L = **165 kg in 24 days,**

x 12 = 1,980 kg/year = **2,000,000 g/year**

One mAb dose = 500 mg = **0.5 g**

2,000,000/0.5 = **4 million doses per reactor per year.**

6 doses per patient per year?

4,000,000/6 = **600,000** patients per year per reactor.

At \$10,000 per patient per year → **\$6B** in sales /per 30KL reactor

Not bad!!